Grant M Henning1, Gerald L Andriole2, Eric H Kim2. 1. Washington University School of Medicine, St. Louis, MO, USA. grant.henning@wustl.edu. 2. Washington University School of Medicine, St. Louis, MO, USA.
Abstract
BACKGROUND: Several liquid biomarker tests have been developed to account for the limitations of prostate specific antigen (PSA) screening prior to prostate biopsy. African ancestry is an established risk factor for prostate cancer (PCa) and must be particularly considered when evaluating patients with liquid biomarkers. While multiple tests have been developed over decades of exploration, recent advances can help patients and physicians incorporate data into a broader clinical context. METHODS: We sought to review currently available liquid biomarker tests in a practical, clinically directed fashion with particular focus on performance in men with African ancestry. We reviewed discovery and validation studies and highlight important considerations for each test. RESULTS: We discuss the advantages and limitations of percent free PSA, Prostate Health Index, Progensa® PCA3, ExoDx® Prostate Test, SelectMDx®, 4Kscore® Test, and Mi-Prostate Score and summarize salient studies on their use. A literature review of evidence specifically for men with African ancestry was conducted and available studies were summarized. CONCLUSIONS: Liquid biomarkers can be useful tools for aiding in risk stratification prior to prostate biopsy. Use of such tests should be individualized based on a thorough knowledge of supporting evidence and the goals of the patient and physician. Further study should prioritize evaluation of such biomarkers in men with African ancestry.
BACKGROUND: Several liquid biomarker tests have been developed to account for the limitations of prostate specific antigen (PSA) screening prior to prostate biopsy. African ancestry is an established risk factor for prostate cancer (PCa) and must be particularly considered when evaluating patients with liquid biomarkers. While multiple tests have been developed over decades of exploration, recent advances can help patients and physicians incorporate data into a broader clinical context. METHODS: We sought to review currently available liquid biomarker tests in a practical, clinically directed fashion with particular focus on performance in men with African ancestry. We reviewed discovery and validation studies and highlight important considerations for each test. RESULTS: We discuss the advantages and limitations of percent free PSA, Prostate Health Index, Progensa® PCA3, ExoDx® Prostate Test, SelectMDx®, 4Kscore® Test, and Mi-Prostate Score and summarize salient studies on their use. A literature review of evidence specifically for men with African ancestry was conducted and available studies were summarized. CONCLUSIONS: Liquid biomarkers can be useful tools for aiding in risk stratification prior to prostate biopsy. Use of such tests should be individualized based on a thorough knowledge of supporting evidence and the goals of the patient and physician. Further study should prioritize evaluation of such biomarkers in men with African ancestry.
Authors: W J Catalona; A W Partin; K M Slawin; M K Brawer; R C Flanigan; A Patel; J P Richie; J B deKernion; P C Walsh; P T Scardino; P H Lange; E N Subong; R E Parson; G H Gasior; K G Loveland; P C Southwick Journal: JAMA Date: 1998-05-20 Impact factor: 56.272
Authors: Richard Lee; A Russell Localio; Katrina Armstrong; S Bruce Malkowicz; J Sanford Schwartz Journal: Urology Date: 2006-04-05 Impact factor: 2.649
Authors: W J Catalona; D S Smith; T L Ratliff; K M Dodds; D E Coplen; J J Yuan; J A Petros; G L Andriole Journal: N Engl J Med Date: 1991-04-25 Impact factor: 91.245
Authors: A A Luderer; Y T Chen; T F Soriano; W J Kramp; G Carlson; C Cuny; T Sharp; W Smith; J Petteway; M K Brawer Journal: Urology Date: 1995-08 Impact factor: 2.649
Authors: Stephen D Mikolajczyk; William J Catalona; Cindy L Evans; Harry J Linton; Lisa S Millar; Kathy M Marker; Diksha Katir; Anna Amirkhan; Harry G Rittenhouse Journal: Clin Chem Date: 2004-03-30 Impact factor: 8.327